Ashley M P, Kotlarski I
Cell Immunol. 1986 Aug;101(1):156-67. doi: 10.1016/0008-8749(86)90194-2.
It has been previously reported from this laboratory that the C57BL/6 melanoma B16 will grow in allogeneic mice provided that donor-derived passenger leukocytes are first removed by in vitro passage of the tumor cells. In this paper we report that allogeneic and syngeneic mice support similar survival of [125I]iododeoxyuridine-labeled B16 cells (125I-B16 cells) as indicated by whole-body retention of 125I. B16 failed to induce the early cytotoxic response which was induced by semiallogeneic peritoneal cells (PC) and by two other allogeneic tumors (EL4 lymphoma and MC-2 sarcoma). They were nevertheless rapidly destroyed by the response induced by PC or EL4. B16 did show some immunogenicity as indicated by regression of some primary B16 tumors (45% ip and the majority of footpad tumors) and by the slow cytotoxic response to secondary 125I-B16 challenge following preimmunization with live or irradiated B16 cells. An equivalent response was induced by preimmunization with a 100-fold lower dose of PC. These findings are discussed in relation to the requirement for inductive stimuli, in addition to antigen, for the stimulation of in vivo cytotoxic responses.
此前本实验室曾报道,若先通过肿瘤细胞的体外传代去除供体来源的过客白细胞,则C57BL/6黑色素瘤B16可在同种异体小鼠体内生长。在本文中,我们报道,同种异体和同基因小鼠对[125I]碘脱氧尿苷标记的B16细胞(125I-B16细胞)的存活支持情况相似,这可通过125I的全身滞留情况来表明。B16未能诱导出由半同种异体腹膜细胞(PC)以及另外两种同种异体肿瘤(EL4淋巴瘤和MC-2肉瘤)所诱导的早期细胞毒性反应。然而,它们会被PC或EL4所诱导的反应迅速破坏。B16确实表现出了一定的免疫原性,这可通过一些原发性B16肿瘤的消退(45%的腹腔内肿瘤以及大多数足垫肿瘤)以及在用活的或经辐照的B16细胞进行预免疫后对二次125I-B16攻击的缓慢细胞毒性反应来表明。用低100倍剂量的PC进行预免疫可诱导出同等反应。除抗原外,还结合诱导刺激对体内细胞毒性反应刺激的需求对这些发现进行了讨论。